EMA Authorised: Plenadren (hydrocortisone) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

The EMA authorised Plenadren (hydrocortisone) for adrenal insufficiency, indicating regulatory approval and listing Takeda as the Marketing Authorisation Holder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Insufficiency

Drugs mentioned

• Plenadren (hydrocortisone, modified-release)

Snippet

Status: Authorised. Therapeutic area: Adrenal Insufficiency. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 28/09/2023